Insulin Lispro

Insulin Lispro, the active ingredient in Insulin Lispro, is a rapid‑acting insulin analog presented as a solution for subcutaneous use. It is used to control blood glucose in people with type 1 and type 2 diabetes mellitus by mimicking natural insulin action.

GNH USA supplies Insulin Lispro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Lispro is a rapid‑acting insulin analog that lowers blood glucose by facilitating cellular uptake.

Type 1 diabetes mellitus: provides mealtime insulin to maintain target glucose levels. Type 2 diabetes mellitus: used as prandial insulin to improve post‑prandial glucose control. Post‑prandial hyperglycemia: helps reduce glucose spikes after meals.

Insulin Lispro may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized thickening or loss of subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological impairment requiring assistance. - Allergic reaction: rash, urticaria, or anaphylaxis. - Serum sickness–like reaction: fever, arthralgia, and lymphadenopathy.

When using Insulin Lispro, several precautions should be observed to ensure safe and effective therapy.

Dose adjustment: tailor insulin dose based on frequent blood glucose monitoring and carbohydrate intake. Renal impairment: monitor closely as reduced clearance may increase hypoglycemia risk. Pregnancy: use only if benefits outweigh potential risks to the fetus. Alcohol consumption: may potentiate hypoglycemia; advise patients to limit intake. Hypoglycemia unawareness: educate patients to recognize early signs and adjust dosing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Lispro can interact with other medicines, altering its glucose‑lowering effect or increasing adverse risks.

Major Interactions (Avoid): - Sulfonylureas: combined use may cause additive hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms, complicating detection. - MAO inhibitors: can potentiate insulin’s glucose‑lowering action.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, requiring dose adjustment. - Corticosteroids: can increase glucose levels, potentially reducing insulin efficacy. - ACE inhibitors: may enhance insulin sensitivity, increasing hypoglycemia risk.